Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18490Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kostapanos, M. S. | en |
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Gazi, I. | en |
| dc.contributor.author | Kostara, C. | en |
| dc.contributor.author | Bairaktari, E. T. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:53:04Z | - |
| dc.date.available | 2015-11-24T18:53:04Z | - |
| dc.identifier.issn | 0091-2700 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18490 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Alpha-Globulins/*urine | en |
| dc.subject | Female | en |
| dc.subject | Fluorobenzenes/*pharmacology | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | en |
| dc.subject | Hyperlipoproteinemia Type II/*drug therapy | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Pyrimidines/*pharmacology | en |
| dc.subject | Sulfonamides/*pharmacology | en |
| dc.title | Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1177/0091270006292629 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17050799 | - |
| heal.identifier.secondary | http://jcp.sagepub.com/content/46/11/1337.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | The renoprotective effect of statins has been recently disputed because of observations of proteinuria associated with rosuvastatin treatment, the newest drug of the class. Statin-induced proteinuria findings were mainly based on crudely quantitative dipstick assays. The authors quantitatively evaluated the effect of rosuvastatin at the recommended starting dose of 10 mg/d, on urine protein excretion in patients with primary dyslipidemia. Serum lipid and nonlipid parameters as well as urinary electrolyte, creatinine, and protein (total, albumin, immunoglobulin G, and alpha-1 microglobulin) levels were measured in 40 patients treated with rosuvastatin and 30 controls at baseline and after 12 weeks. The protein-to-creatinine ratios were used to assess urinary protein excretion. Rosuvastatin improved the lipid profile, produced no deterioration of kidney function, but induced a small but significant increase in the excretion of alpha-1 microglobulin (by 16%, P < .05) indicating that statin-related proteinuria involves low-molecular-weight proteins and is of proximal tubular origin. | en |
| heal.journalName | J Clin Pharmacol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kostapanos-2006-Rosuvastatin increas.pdf | 102.54 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
